Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Natera Inc. Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40.03 (market cap $135.56M), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 420.7× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Natera Inc. Common Stock for 0 Days on average.
| GPTY | NTRA | |
|---|---|---|
Market Cap | $135.56M | $57.03B |
Volume | 66,044 | 1,131,157 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $425.64 |
52-Week Low | $34.73 | $179.42 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
